Australia's Race Oncology plunges on chief scientific officer's exit

Racura Oncology

24/03/2023 03:03

** Shares of pharma co Race Oncology Ltd  RAC.AX  drop as
much as 17.3% to A$1.65, their worst intraday loss since May 20,
2020
    ** Co says chief scientific officer and executive director
Daniel Tillett has stepped down from both roles, after nearly
four years in the roles
    ** Adds Tim Hammond, a former AstraZeneca executive, will be
interim chief scientific officer
    ** Stock hits lowest level since June 23, 2022
    ** Trading volumes near 6 times the 30-day average, with
about 805,000 shares traded so far
    ** As of last close, stock down 0.8% YTD

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))